Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

A warning against over-interpretation of seasonal signals measured by the Global Navigation Satellite System.

Chanard K, Métois M, Rebischung P, Avouac JP.

Nat Commun. 2020 Mar 13;11(1):1375. doi: 10.1038/s41467-020-15100-7. No abstract available.

2.

Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?

Elhai M, Avouac J, Allanore Y.

Semin Arthritis Rheum. 2020 Jan 28. pii: S0049-0172(20)30006-8. doi: 10.1016/j.semarthrit.2020.01.006. [Epub ahead of print] Review.

PMID:
32089354
3.

Cascading and pulse-like ruptures during the 2019 Ridgecrest earthquakes in the Eastern California Shear Zone.

Chen K, Avouac JP, Aati S, Milliner C, Zheng F, Shi C.

Nat Commun. 2020 Jan 7;11(1):22. doi: 10.1038/s41467-019-13750-w.

4.

Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database.

Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Siegert E, Lazzaroni MG, Carreira PE, Vettori S, Zanatta E, Ullman S, Czirjàk L, Kowal-Bielecka O, Distler O, Matucci-Cerinic M, Allanore Y; EUSTAR co-authors.

Autoimmun Rev. 2020 Feb;19(2):102452. doi: 10.1016/j.autrev.2019.102452. Epub 2019 Dec 12.

PMID:
31838157
5.

Similar scaling laws for earthquakes and Cascadia slow-slip events.

Michel S, Gualandi A, Avouac JP.

Nature. 2019 Oct;574(7779):522-526. doi: 10.1038/s41586-019-1673-6. Epub 2019 Oct 23.

PMID:
31645722
6.

Systemic sclerosis: Recent insight in clinical management.

Zanatta E, Codullo V, Avouac J, Allanore Y.

Joint Bone Spine. 2019 Sep 27. pii: S1297-319X(19)30145-9. doi: 10.1016/j.jbspin.2019.09.015. [Epub ahead of print]

PMID:
31568838
7.

Estrogens Counteract the Profibrotic Effects of TGF-β and their Inhibition Exacerbates Experimental Dermal Fibrosis.

Avouac J, Pezet S, Gonzalez V, Baudoin L, Cauvet A, Ruiz B, Boleto G, Brandely ML, Elmerich M, Allanore Y.

J Invest Dermatol. 2020 Mar;140(3):593-601.e7. doi: 10.1016/j.jid.2019.07.719. Epub 2019 Aug 31.

PMID:
31476316
8.

Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.

Fasano S, Riccardi A, Messiniti V, Caramaschi P, Rosato E, Maurer B, Smith V, Siegert E, De Langhe E, Riccieri V, Airó P, Mihai C, Avouac J, Zanatta E, Walker UA, Iannone F, García De la Peña Lefebvre P, Distler JHW, Vacca A, Distler O, Kowal-Bielecka O, Allanore Y, Valentini G.

Ann Rheum Dis. 2019 Dec;78(12):1681-1685. doi: 10.1136/annrheumdis-2019-215787. Epub 2019 Aug 17.

PMID:
31422354
9.

Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.

Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, Matucci-Cerinic M, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirják L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli A, Krummel-Lorenz B, Rednic S, Allanore Y, Müeller-Ladner U.

Ann Rheum Dis. 2019 Nov;78(11):1576-1582. doi: 10.1136/annrheumdis-2019-215486. Epub 2019 Aug 7.

PMID:
31391176
10.

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirják L, Denton CP, Distler O, Allanore Y, Müller-Ladner U, Moggi-Pignone A, Matucci-Cerinic M, Del Galdo F; EUSTAR co-workers.

Clin Rheumatol. 2020 Jan;39(1):27-36. doi: 10.1007/s10067-019-04564-8. Epub 2019 May 20.

PMID:
31111363
11.

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.

Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB.

J Clin Med. 2019 Apr 15;8(4). pii: E515. doi: 10.3390/jcm8040515.

12.

Stabilization of fault slip by fluid injection in the laboratory and in situ.

Cappa F, Scuderi MM, Collettini C, Guglielmi Y, Avouac JP.

Sci Adv. 2019 Mar 13;5(3):eaau4065. doi: 10.1126/sciadv.aau4065. eCollection 2019 Mar.

13.

The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding.

Mouasni S, Gonzalez V, Schmitt A, Bennana E, Guillonneau F, Mistou S, Avouac J, Ea HK, Devauchelle V, Gottenberg JE, Chiocchia G, Tourneur L.

Cell Death Dis. 2019 Feb 25;10(3):190. doi: 10.1038/s41419-019-1412-9.

14.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirják L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, Matucci-Cerinic M; EUSTAR co-workers.

Arthritis Res Ther. 2019 Jan 24;21(1):35. doi: 10.1186/s13075-019-1822-1.

15.

Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.

Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg Ø, Allanore Y.

Arthritis Rheumatol. 2019 Jun;71(6):972-982. doi: 10.1002/art.40815. Epub 2019 Apr 26.

PMID:
30624031
16.

Targeting Costimulatory Pathways in Systemic Sclerosis.

Boleto G, Allanore Y, Avouac J.

Front Immunol. 2018 Dec 18;9:2998. doi: 10.3389/fimmu.2018.02998. eCollection 2018. Review.

17.

Bimodal seismicity in the Himalaya controlled by fault friction and geometry.

Dal Zilio L, van Dinther Y, Gerya T, Avouac JP.

Nat Commun. 2019 Jan 3;10(1):48. doi: 10.1038/s41467-018-07874-8.

18.

Regulatory T Cells in Systemic Sclerosis.

Frantz C, Auffray C, Avouac J, Allanore Y.

Front Immunol. 2018 Oct 15;9:2356. doi: 10.3389/fimmu.2018.02356. eCollection 2018. Review.

19.

18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis.

Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, Blagojevic J, Moggi-Pignone A, Mihai C, Avouac J, Passeri A, De Cristofaro MT, Distler O, Allanore Y, Guiducci S, Matucci-Cerinic M.

Ann Rheum Dis. 2019 Apr;78(4):577-578. doi: 10.1136/annrheumdis-2018-213376. Epub 2018 Oct 18. No abstract available.

PMID:
30337426
20.

European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.

Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, Matucci-Cerinic M, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F.

Rheumatology (Oxford). 2019 Feb 1;58(2):254-259. doi: 10.1093/rheumatology/key271.

21.

Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis.

Leblond A, Pezet S, Trouvin AP, Elhai M, Gonzalez V, Allanore Y, Avouac J.

PLoS One. 2018 Sep 6;13(9):e0203607. doi: 10.1371/journal.pone.0203607. eCollection 2018.

22.

From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey.

Vasile M, Avouac J, Sciarra I, Stefanantoni K, Iannace N, Cravotto E, Valesini G, Allanore Y, Riccieri V.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):82-87. Epub 2018 Aug 29.

PMID:
30183599
23.

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.

Boleto G, Guignabert C, Pezet S, Cauvet A, Sadoine J, Tu L, Nicco C, Gobeaux C, Batteux F, Allanore Y, Avouac J.

Arthritis Res Ther. 2018 Aug 29;20(1):197. doi: 10.1186/s13075-018-1694-9.

24.

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.

Frantz C, Pezet S, Avouac J, Allanore Y.

Dis Markers. 2018 Apr 1;2018:8509583. doi: 10.1155/2018/8509583. eCollection 2018.

25.

Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.

Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, Kahan A, Dieude P, Allanore Y.

Semin Arthritis Rheum. 2018 Oct;48(2):149-154. doi: 10.1016/j.semarthrit.2018.02.010. Epub 2018 Feb 21.

PMID:
29548542
26.

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.

Avouac J, Moltó A, Abitbol V, Etcheto A, Salcion A, Gutermann L, Klotz C, Elhai M, Cohen P, Soret PA, Morin F, Conort O, Chast F, Goulvestre C, Jeunne CL, Chaussade S, Kahan A, Roux C, Allanore Y, Dougados M.

Semin Arthritis Rheum. 2018 Apr;47(5):741-748. doi: 10.1016/j.semarthrit.2017.10.002. Epub 2017 Oct 5.

PMID:
29102156
27.

Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study.

John G, Avouac J, Piantoni S, Polito P, Fredi M, Cozzi F, Airò P, Truchetet ME, Franceschini F, Allanore Y, Chizzolini C.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1218-1227. doi: 10.1002/acr.23454. Epub 2018 Jun 19.

28.

The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study.

John G, Allanore Y, Polito P, Piantoni S, Fredi M, Avouac J, Franceschini F, Truchetet ME, Cozzi F, Airo P, Chizzolini C.

Rheumatology (Oxford). 2017 Nov 1;56(11):1874-1883. doi: 10.1093/rheumatology/kex230.

PMID:
28977630
29.

Mapping and predicting mortality from systemic sclerosis.

Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, Cozzi F, Ullman S, Czirják L, Tikly M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Szücs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, De Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, García de la Peña Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y; EUSTAR group.

Ann Rheum Dis. 2017 Nov;76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448. Epub 2017 Aug 23.

PMID:
28835464
30.

Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis.

Avouac J, Guignabert C, Hoffmann-Vold AM, Ruiz B, Dorfmuller P, Pezet S, Amar O, Tu L, Van Wassenhove J, Sadoine J, Launay D, Elhai M, Cauvet A, Subramaniam A, Resnick R, Hachulla E, Molberg Ø, Kahan A, Humbert M, Allanore Y.

Arthritis Rheumatol. 2017 Nov;69(11):2209-2221. doi: 10.1002/art.40229. Epub 2017 Oct 17.

31.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y.

Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.

PMID:
28801346
32.

Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group.

Jaeger VK, Distler O, Maurer B, Czirják L, Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton C, Nihtyanova S, Allanore Y, Avouac J, Riemekasten G, Siegert E, Huscher D, Matucci-Cerinic M, Guiducci S, Frerix M, Tarner IH, Garay Toth B, Fankhauser B, Umbricht J, Zakharova A, Mihai C, Cozzi F, Yavuz S, Hunzelmann N, Rednic S, Vacca A, Schmeiser T, Riccieri V, García de la Peña Lefebvre P, Gabrielli A, Krummel-Lorenz B, Martinovic D, Ancuta C, Smith V, Müller-Ladner U, Walker UA.

Rheumatology (Oxford). 2018 Mar 1;57(3):441-450. doi: 10.1093/rheumatology/kex182.

PMID:
28499034
33.

Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis.

Beyer C, Huscher D, Ramming A, Bergmann C, Avouac J, Guiducci S, Meier F, Vettori S, Siegert E, Jaeger VK, Maurer B, Riemekasten G, Walker U, Müller-Ladner U, Valentini G, Matucci-Cerinic M, Allanore Y, Distler O, Schett G, Distler JHW.

Ann Rheum Dis. 2018 Apr;77(4):626-628. doi: 10.1136/annrheumdis-2016-210834. Epub 2017 May 11. No abstract available.

PMID:
28495672
34.

Targeting synovial neoangiogenesis in rheumatoid arthritis.

Leblond A, Allanore Y, Avouac J.

Autoimmun Rev. 2017 Jun;16(6):594-601. doi: 10.1016/j.autrev.2017.04.005. Epub 2017 Apr 14. Review.

PMID:
28414154
35.

Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis.

Avouac J, Lepri G, Smith V, Toniolo E, Hurabielle C, Vallet A, Amrouche F, Kahan A, Cutolo M, Allanore Y.

Semin Arthritis Rheum. 2017 Aug;47(1):86-94. doi: 10.1016/j.semarthrit.2017.02.006. Epub 2017 Feb 10.

PMID:
28291582
36.
37.

Update of EULAR recommendations for the treatment of systemic sclerosis.

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors.

Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.

38.

Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years.

Avouac J, Amrouche F, Meune C, Rey G, Kahan A, Allanore Y.

Semin Arthritis Rheum. 2017 Apr;46(5):537-543. doi: 10.1016/j.semarthrit.2016.10.007. Epub 2016 Oct 29.

PMID:
27908535
39.

Effects of rituximab in connective tissue disorders related interstitial lung disease.

Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, Garcia Hernàndez F, Gonzalez Nieto JA, Guiducci S, Jordan S, Limaye V, Maurer B, Selva-O'Callaghan A, Riccieri V, Distler O, Matucci-Cerinic M, Allanore Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):181-185. Epub 2016 Oct 14.

40.

A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis.

Koumakis E, Bouaziz M, Dieudé P, Cauvet A, Ruiz B, Airò P, Cusi D, Matucci-Cerinic M, Salvi E, Cuomo G, Hachulla E, Diot E, Caramaschi P, Riccieri V, Avouac J, Allanore Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):43-48. Epub 2016 Jul 1.

PMID:
27385538
41.

Time scale bias in erosion rates of glaciated landscapes.

Ganti V, von Hagke C, Scherler D, Lamb MP, Fischer WW, Avouac JP.

Sci Adv. 2016 Oct 5;2(10):e1600204. eCollection 2016 Oct.

42.

The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.

Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y.

Ann Rheum Dis. 2017 Jan;76(1):270-276. doi: 10.1136/annrheumdis-2016-209768. Epub 2016 Sep 12.

PMID:
27621285
43.

N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis.

Allanore Y, Komocsi A, Vettori S, Hachulla E, Hunzelmann N, Distler J, Avouac J, Gobeaux C, Launay D, Czirjak L, Kahan A, Meune C.

Int J Cardiol. 2016 Nov 15;223:385-389. doi: 10.1016/j.ijcard.2016.08.246. Epub 2016 Aug 13.

PMID:
27543715
44.

OX40L blockade protects against inflammation-driven fibrosis.

Elhai M, Avouac J, Hoffmann-Vold AM, Ruzehaji N, Amiar O, Ruiz B, Brahiti H, Ponsoye M, Fréchet M, Burgevin A, Pezet S, Sadoine J, Guilbert T, Nicco C, Akiba H, Heissmeyer V, Subramaniam A, Resnick R, Molberg Ø, Kahan A, Chiocchia G, Allanore Y.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3901-10. doi: 10.1073/pnas.1523512113. Epub 2016 Jun 13.

45.

Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey.

Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, Connolly K, Varga J, Matucci-Cerinic M, Allanore Y.

Semin Arthritis Rheum. 2016 Aug;46(1):115-23. doi: 10.1016/j.semarthrit.2016.02.005. Epub 2016 Feb 26.

PMID:
27132536
46.

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.

Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, Luccarini JM, Broqua P, Junien JL, Allanore Y.

Ann Rheum Dis. 2016 Dec;75(12):2175-2183. doi: 10.1136/annrheumdis-2015-208029. Epub 2016 Mar 9.

47.

Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.

Ponsoye M, Frantz C, Ruzehaji N, Nicco C, Elhai M, Ruiz B, Cauvet A, Pezet S, Brandely ML, Batteux F, Allanore Y, Avouac J.

Ann Rheum Dis. 2016 Dec;75(12):2142-2149. doi: 10.1136/annrheumdis-2015-208213. Epub 2016 Feb 24.

PMID:
26912566
48.

Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension.

Huertas A, Phan C, Bordenave J, Tu L, Thuillet R, Le Hiress M, Avouac J, Tamura Y, Allanore Y, Jovan R, Sitbon O, Guignabert C, Humbert M.

Chest. 2016 Jun;149(6):1482-93. doi: 10.1016/j.chest.2016.01.004. Epub 2016 Jan 21.

PMID:
26836928
49.

Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis.

Aïssou L, Meune C, Avouac J, Meunier M, Elhaï M, Sorbets E, Kahan A, Allanore Y.

Joint Bone Spine. 2016 Jul;83(4):444-7. doi: 10.1016/j.jbspin.2015.09.003. Epub 2015 Dec 29.

PMID:
26750764
50.

Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease.

Hurabielle C, Avouac J, Lepri G, de Risi T, Kahan A, Allanore Y.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1021-7. doi: 10.1002/acr.22766.

Supplemental Content

Loading ...
Support Center